---
title: "Yili Chuanning Biotechnology Co., Ltd. (301301.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301301.SZ.md"
symbol: "301301.SZ"
name: "Yili Chuanning Biotechnology Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-21T09:21:14.315Z"
locales:
  - [en](https://longbridge.com/en/quote/301301.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301301.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301301.SZ.md)
---

# Yili Chuanning Biotechnology Co., Ltd. (301301.SZ)

## Company Overview

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.klcnsw.com](https://www.klcnsw.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.52)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -20.21% |  |
| Net Profit YoY | -55.72% |  |
| P/B Ratio | 2.56 |  |
| Dividend Ratio | 4.71% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 20900242144.22 |  |
| Revenue | 4405333351.02 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.22% | B |
| Profit Margin | 13.40% | B |
| Gross Margin | 23.56% | C |
| Revenue YoY | -20.21% | E |
| Net Profit YoY | -55.72% | D |
| Total Assets YoY | -3.07% | D |
| Net Assets YoY | 0.14% | D |
| Cash Flow Margin | 104.00% | C |
| OCF YoY | -20.21% | E |
| Turnover | 0.42 | C |
| Gearing Ratio | 21.00% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Yili Chuanning Biotechnology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-20.21%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-55.72%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.56",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.71%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "20900242144.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4405333351.02",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.22%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.40%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "23.56%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-20.21%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-55.72%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.07%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.14%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "104.00%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-20.21%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.00%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.40 | 15/81 | 27.14 | 24.50 | 21.16 |
| PB | 2.56 | 39/81 | 3.34 | 3.14 | 2.90 |
| PS (TTM) | 4.74 | 20/81 | 5.25 | 5.06 | 4.89 |
| Dividend Yield | 4.71% | 3/81 | 2.61% | 2.44% | 2.24% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-08T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.23 |
| Highest Target | 14.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301301.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301301.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301301.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301301.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**